YALE INNOVATION SUMMIT
PRESENTED BY THE YALE OFFICE OF COOPERATIVE RESEARCH
WEDNESDAY
MAY 8, 2019
8AM-5PM
YALE SCHOOL OF MANAGEMENT
5-7:30PM
RECEPTION
YALE PEABODY MUSEUM

THE MOST SIGNIFICANT GATHERING OF EARLY-STAGE INVESTORS ON YALE'S CAMPUS
ABOUT THE YALE INNOVATION SUMMIT

The Yale Innovation Summit is an event highlighting entrepreneurial Yale faculty and students and the investable innovations coming out of Yale labs. The event includes a Biotech Track, aimed at those interested in commercializing ideas for drug discovery and biological therapeutics, and a Tech Track, for those interested in commercializing ideas from physical and computer sciences, engineering, software and services. In both cases, the emphasis is on developing fundable ideas and taking an entrepreneurial approach to engaging with pharmaceutical companies and venture capitalists.

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keynote</td>
<td>5</td>
</tr>
<tr>
<td>Schedule</td>
<td>8</td>
</tr>
<tr>
<td>Pitch Line Up</td>
<td>10</td>
</tr>
<tr>
<td>CT Innovation Pitch</td>
<td>12</td>
</tr>
<tr>
<td>Tech Panels</td>
<td>14</td>
</tr>
<tr>
<td>Bio Panels</td>
<td>15</td>
</tr>
<tr>
<td>E-Posters</td>
<td>16</td>
</tr>
</tbody>
</table>

*Program book as of April 29, 2019*
About The Blavatnik Fund
For Innovation at Yale

The Blavatnik Fund for Innovation at Yale, a $25 million fund, bridges the gap between innovative, early-stage life science research and successful development of high-impact biomedical product.

The Blavatnik Fund for Innovation at Yale supports Yale faculty in the commercialization of applied research and technology in the life sciences. A significant obstacle to the development of early-stage university discoveries is the lack of funding for the proof-of-concept and validation studies needed to demonstrate commercial potential. To overcome this barrier, the Fund provides funding and business development support to help validate nascent technologies and identify potential industry partners to advance these technologies to the marketplace.

The Fund seeks to support innovative, investigator-initiated research aimed at extending preliminary observations, with proof-of-concept and the generation of robust intellectual property as key objectives. The Fund is designed to accommodate projects of varying magnitude, as appropriate. Its primary goal is to advance technologies to the point where additional support from industry and/or technology transfer is achieved. Supported projects may include such areas as therapeutics, diagnostics/biomarkers, medical devices, or research instruments, among others.

The expected goal of completed projects will be partnerships with industry, through licenses to existing biopharmaceutical companies and startup firms (some launched from the Fund-supported technology) or via major industry-sponsored research agreements. It is expected that these alliances will lead to additional industry-sponsored research support. The Fund is structured as a sustainable, “evergreen” program, with a portion of the revenue from successfully launched technologies cycled back to support ongoing and future Fund projects.

The Blavatnik Fund is supported by a grant from the Blavatnik Family Foundation.
The Blavatnik Fellowship in Life Science Entrepreneurship is designed to foster entrepreneurial skills in the life sciences, linking emerging business leaders with breakthrough innovations from across Yale University. The Blavatnik Fellows work side-by-side with past Blavatnik awardees and applicants as well as participate in screening for this coming year’s applicants, sit with board members during deliberation, and work with a number of Entrepreneurs-in-Residence to ready faculty for final applications.

Thank you to our 2018-2019 Blavatnik fellows!

Sorin Fedeles, Ph.D., M.B.A
Caroline Rufo, Ph.D.
Timothy Siegert, Ph.D.
Milica Vukmirovic, Ph.D.

The 2019-2020 Blavatnik fellows will be announced at the awards ceremony today!
Welcome to the 2019 Innovation Summit
Words from the Managing Director of OCR

Welcome to the 5th Annual Yale Innovation Summit hosted by the Office of Cooperative Research at Yale.

On behalf of the Office of Cooperative Research and Yale University, I’d like to thank you all for being a part of our innovation ecosystem. We’re thrilled to have you as partners and supporters as we continue down that path of being a leader in research, innovation, and marketization.

This year’s Summit marks the fifth year that we’ve been bringing industry leaders, investors, faculty, and students together to share ideas, network, and highlight some of Yale's most investible projects. Since the beginning, we’ve committed ourselves to ensuring that this conference is of value to all who attend, and we’re excited to continue bringing insightful panels, amazing keynotes, and showcasing the dozens of promising opportunities coming out of Yale laboratories.

The Summit has become the signature event highlighting the innovation ecosystem being fostered around Yale and New Haven. Last year’s Summit was noted for its energy and impact as evidenced by 1000+ attendees. This year’s Summit will continue to feature dual tracks for biotechnology and technology companies with keynote presentations from Annie Lamont, Oak HC/FT Co-Founder & Managing Partner; Sean Harper, MD, Managing Director of Westlake Village Biopartners; and Kate Bingham, Managing Partner of SV Health Investors.

We are eager to have each attendee join in the broader conversation around opportunities for growing, strengthening and enhancing the environment for fostering more entrepreneurial enterprises in the State. We have had some success already.

In the past decade, entrepreneurs launched 130 ventures based on Yale discoveries that have received over $500 in investment capital; in 2017, 11 new companies were created. The companies launched since 2003 raised $1.4 billion.

For example:

- Arvinas raised over $110 million in venture capital and received $74 million from licensing agreements with Pfizer, Genentech, and Merck; these agreements include $1.4 billion in potential milestone payments. It raised $120 million in an IPO in September 2018.
- BioHaven Pharmaceuticals raised over $193.5 million in an IPO in May 2017 and an additional $150 million in a royalty funding stock purchase deal with Royalty Pharma.
- Quantum Circuits, Inc., raised $18 million led by Canaan Partners and Sequoia, has a staff of 15, and is working to “develop, manufacture, and sell the first practical quantum computers.”
- Other companies include Cybrexa (oncology), IsoPlexis (research instruments), Ancera (food safety), Artizan Bioscience (microbiome therapy), Kleo Pharmaceuticals (immuno-oncology), and P2 Science (green chemicals).

We’re excited to continue the momentum we’ve seen over the years and we’re thrilled to have partners like you supporting us every step of the way.

Enjoy this year’s Innovation Summit.

Jon Soderstrom
Jon Soderstrom
Managing Director
Yale University Office of Cooperative Research
Oak HC/FT Co-Founder & Managing Partner, Annie Lamont has more than 30 years of experience as a venture capitalist investing in transformative companies and entrepreneurs.

In 2014, Annie, along with Patricia Kemp and Andrew Adams, launched Oak HC/FT, a venture capital firm that invests in early to growth stage tech-enabled companies shaping the future of healthcare information and financial services. Before founding Oak HC/FT, Annie was a Managing Partner at Oak Investment Partners.

Annie is known as a leading healthcare and fintech investor, appearing on the Forbes Midas List, Institutional Investor’s FinTech Finance 40 list, and the Top 100 Venture Capitalist rankings published by CB Insights and The New York Times. She was the first recipient of the National Venture Capital Association’s award for Excellence in Healthcare Innovation. Annie was also honored with Healthcare Private Equity Association’s 2017 Russell L. Carson Award for lifetime achievement in healthcare investing. Annie serves as a core participant of the Health and Human Services Deputy Secretary’s Innovation and Investment Summit (DSIIS), a collaboration between HHS and healthcare innovation and investment professionals to discuss the healthcare landscape, emerging opportunities, and the government’s role in facilitating accelerated innovation and investment.

She serves on the board of HCA, one of the world’s leading healthcare companies, and previously served on the Stanford Board of Trustees.

Annie received her bachelor’s degree in political science from Stanford University.
Dr. Sean Harper’s career has been driven by one central mission, which he gives as advice to entrepreneurs: “Focus on profound unmet medical needs, rather than market projections. Fill those needs and the rest will follow.”

Named by Time as one of the 50 most influential people in healthcare in 2018, Harper has helped bring well over a dozen novel therapies to patients during his career. In areas as diverse as oncology, osteoporosis, cardiovascular disease and migraine, Harper’s passion for science and medicine has benefited millions of patients worldwide.

Harper brings a rare breadth of experience to Westlake Village BioPartners. He has experience in both basic research and as a practicing physician. He has led a wide range of clinical research programs, extending from early translational trials to global outcomes studies. As managing director, Harper will use this breadth of experience to identify promising new therapies and technologies and launch life sciences companies to address significant unmet medical needs.

From 2002 to 2018, Harper worked for Amgen, rising to become head of R&D in 2012. In that role, he managed investments of more than $3.5 billion annually, applying breakthroughs in science to address some of society’s biggest health challenges.

Harper put Amgen on the leading edge of the industry in a number of notable areas, including utilizing the increasing understanding of human genetics in drug target identification and validation and developing novel platforms and modalities to target some of the most difficult-to-treat diseases. Harper was involved in the strategic deployment of Amgen’s venture capital funds, acquisitions of smaller biotech companies, and licensing opportunities.

Earlier in his time at Amgen, Harper held a number of key leadership positions, including establishing the translational medicine group focused on biomarker discovery, development and integration into early-stage clinical studies. He also held positions as head of Global Regulatory Affairs and Safety, and head of Global Development/Corporate Chief Medical Officer.
In her 26 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. She is one of five Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund (with greater than $2 billion in total assets) for life sciences investing in US and Europe. Kate is responsible for biotech investments and activities in the EU and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. These investments include small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas.

Kate played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.

**PRIOR EXPERIENCE**
Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.

**ACADEMIC CREDENTIALS**
First class degree, Biochemistry, Oxford University; MBA, Harvard Business School (Baker Scholar).

**OUTSIDE OF SV**
Kate won the Lifetime Achievement Award, presented by BioIndustry Association UK in January 2017. Kate also serves on the Board of the Francis Crick Institute, serves as Deputy Chairman of St Paul’s Girls’ School, London, and sits on the Advisory Committee of Oxford University Spin-out Equity Management (OSEM). At weekends Kate spends time in Wales where she rides horses and mountain bikes, grows vegetables and competes in bog snorkeling competitions.
2019 SUMMIT LINE-UP
Wednesday May 8, 2019, Yale School of Management

7:00AM ● REGISTRATION, BREAKFAST & NETWORKING
Continental Breakfast - Charley’s Place
The Innovators Breakfast:
Networking 101 from a Woman in Venture Capital - Beinecke Room

8:00AM ● KICKOFF & OPENING KEYNOTE
Annie Lamont | Co-Founder & Managing Partner, Oak HC/FT - Zhang

9:10AM ● PANEL SESSION ONE
Biotech: Breadth vs. Depth of Assets/Platform in Value Creation - Zhang
Tech: Digital Health Trends and Opportunities - Room 2400
Connecticut Innovations: Portfolio Pitches (Therapeutics & DX) - Room 2410

10:10AM ● PANEL SESSION TWO
Tech: Where will A.I. replace N.I.? - Room 2400
Connecticut Innovations: Portfolio Pitches (Therapeutics & DX cont.) - Room 2410

11:00AM ● COURTYARD ACTIVITIES
e-Posterboard Session
Lunch & Networking

12:30PM ● AFTERNOON KEYNOTE
Sean Harper | Managing Director, Westlake Village Biopartners - Zhang
1:30PM  **PITCH HOUR**
Biotech: Pitch Contest - Zhang
Tech: Pitch Contest - Room 2400
Connecticut Innovations: Portfolio Pitches (Med Dev, Healthcare IT, & Chem) - Room 2410

3:00PM  **PANEL SESSION THREE**
Biotech: Hot Areas for Investment and Why - Zhang
Tech: Rise of the Family Office: Shaking up the Investment Landscape - Room 2400
Connecticut Innovations: Portfolio Pitches (Tech & Energy) - Room 2410

4:00PM  **CLOSING KEYNOTE & AWARD CEREMONY** - Zhang
Kate Bingham | Managing Partner, SV Health Partners
Tech & Biotech Pitch Awards presentation
2019 Blavatnik Award Announcements

5:00PM  **SUMMIT RECEPTION** - Peabody Museum
Peabody Museum Reception
Poster Prizes
BIOTECH PITCH CONTEST
Zhang Auditorium

Moderator
Rob Bettigole, Elm Street Ventures

EliV5 Therapeutics
Choukri Ben Mamoun
Breakthrough Therapy for Radical Cure of Infection Infections

Immunaxis
Eric Song
Leveraging meningeal lymphatics to treat brain cancer

Statera Therapeutics
Sean Bickerton & Philip Kong
Spatiotemporally Tuned Nanoparticles for unlocking the true potential of immunotherapy in autoimmune diseases

Cytosolix, Inc.
John Deacon
Improving small molecule therapy through targeted drug delivery to solid tumors

Pearl Bio
Natalie Ma & Farren Isaacs
Transforming therapeutics and biomaterials development with synthetic biology

TargetSite Therapeutics
Jeffrey Bender
TargetSite Therapeutics: Harnessing the power of RNA-targeted oligonucleotide therapeutics

Lkit Therapeutics
Ya Ha & Jonathan Ellman
A Novel Strategy to Target p53 Mutation in Human Cancer

Periozyme
Demetrios Braddock
Treating the Root Cause of Periodontal Disease through Cementum Regeneration
TECH PITCH CONTEST
Room 2400

Moderator
Lena Bae, Wiggin and Dana

**NuStent**
Albert Sinusas
Imageable Magnetic Biodegradable Intravascular Scaffold for Treatment of Atherosclerosis

**NeuroProbe**
Hitten Zaveri
Reinventing Brain Care in the 21st Century

**HYPNOS**
Vivek Rajarathnam
Wearable EEG for fatigue management and error prevention

**UNS**
Jonathan Hochman
Universal Name System

**PAP-VR**
Jiheum Park
Transcatheter mitral valve repair system

**AIMI**
Chi Liu
Artificial Intelligent Medical Imaging

**ACIS**
Amir Mor
Automated cell injection systems

**Lumme**
Sherry McKee
Smoking cessation wearable
Therapeutics & DX

Kleo’s proprietary next-generation biospecific drugs are designed to destroy cancer cells by bridging interactions with immune effectors. Its small-molecule/synthetic peptide-based compounds, which function like highly complex biologics, are versatile (smaller and tunable) and modular (faster/less costly to develop). Not only do Kleo’s biospecific drugs offer improved safety and efficacy, but they are also nonimmunogenic (for better dosing) and lead to enhanced tumor penetration.

Based on the Nobel Prize winning science of Dr. Peter Agre, Aeromics is advancing a revolutionary understanding of water physiology to develop first-in-class therapeutics. By inhibiting Aquaporin-4, the water channel found at the blood-brain barrier, Aeromics’ small-molecule AER-271 seeks to control brain swelling (or cerebral edema), which is responsible for 60 to 80 percent of the morbidity and mortality in stroke. Cerebral edema is also an important contributor to the damage caused by traumatic brain and spinal cord injury, glioma, meningitis and neurosurgery. Aeromics has recently completed dosing in a Phase I trial, investigating the safety, tolerability and pharmacokinetics of AER-271.

ReNetX Bio, is creating disease-modifying therapeutics to restore neuronal connections in the central and ocular nervous systems. Three key inhibitory proteins have been identified as central drivers preventing neural regrowth due to binding with NgR1 (Nogo Pathway). With ReNetX Bio’s approach, when these inhibitors are blocked, neural plasticity as well as new axonal growth is triggered. These new neural connections enable rewiring and reversal of damage in the central nervous system. ReNetX Bio’s world-class team of executives and scientific advisers has had positive results in several pre-clinical disease models and independent validation in leading academic and industry labs.

Thetis is developing a novel, potentially disease-modifying oral therapy for inflammatory bowel disease (IBD). Enabled by the proprietary HEALER technology platform, TP-317 is a new molecular entity. TP-317 delivers Resolvin E1, an endogenous lipid mediator that regulates multiple inflammatory processes implicated in IBD pathogenesis, including proinflammatory cytokine expression, clearance of infiltrating immune cells and bacteria, and epithelial tissue repair. Together, these properties suggest an ability to maintain barrier integrity and promote mucosal healing, a fundamental goal of IBD clinical management. TP-317 is a safe, oral therapy for IBD patients needing an alternative to aggressive immunosuppressive agents.

Cybrexa is passionate about bringing new treatment options to help more cancer patients live longer, more fulfilling lives. Cybrexa Therapeutics is an oncology-focused biotech developing a new class of therapeutics based on its alphalux™ platform. This platform allows small-molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors. It enables intracellular, antigen-independent targeting of tumor cells with existing anti-cancer agents. The initial application of this platform is focused on DNA damage repair (DDR) inhibitors.

10:00 AM | Therapeutics & DX (con’t)

Azitra is a clinical-stage biotechnology company combining the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its consumer health and pharmaceutical programs to treat atopic dermatitis, dry skin, cancer therapy associated skin rashes and targeted orphan indications.

OncoSynergy is a venture-backed, clinical-stage oncology company and recent JLABS @SSF graduate. Its lead program, OS2966, has been awarded two orphan designations, and the Food and Drug Administration has approved the investigational new drug application for the initial phase 1 clinical trial in the treatment of recurrent glioblastoma, which will begin in summer 2019.

CaroGen is developing transformative immunotherapies for infectious diseases and cancer, initially focusing on a potential cure for patients chronically infected with hepatitis B virus (HBV). CaroGen’s novel artificial virus platform, virus-like-vesicle (VLV), licensed from Yale School of Medicine, has yielded a clinical candidate dubbed CARG-201 to potentially cure HBV. CaroGen aims to advance CARG-201 to the end of phase I human clinical trial, establishing safety and POC biomarkers efficacy by the end of 2021. In addition, CaroGen is investigating VLV-delivering cytokine in colorectal and ovarian cancers in collaborations with scientists from Yale and UConn Health.

IsoPlexis is employing personalized immunotherapies to combat the toughest diseases. Its integrated systems are changing cancer research by connecting biological readouts to what is actually happening in patients. Its game-changing hardware technologies, combined with its next-generation software and data visualizations, are powered by its R&D team and used throughout the world. IsoPlexis works with a growing list of leading researchers who are publishing findings that connect readouts to what is truly happening in patients.

Tangen has developed an innovative platform that enables molecular diagnostic technology to move out of traditional laboratories by providing low-cost, portable, and rapid diagnostic capabilities for a variety of applications. The Tangen Molecular Diagnostic System (TangenDX™) fills the need for truly flexible nucleic acid-based diagnostic devices. TangenDX™ has the capability to detect a broad array of targets simultaneously on a single sample, while maintaining low cost, easy workflow, and extreme sensitivity. A technology like TangenDX™ will eventually bring high-quality molecular testing to clinics, doctor’s offices, and pharmacies.
Avitus Orthopaedics is a medical device company developing novel instruments for minimally invasive surgery. The company was founded by surgeons and engineers at Johns Hopkins University who sought to develop a superior method for bone graft harvesting. Its flagship product, the Avitus® Bone Harvester, is revolutionizing autograft harvesting by empowering surgeons to deliver the best bone graft for their patients while providing significant cost savings to hospitals. Validated by over 900 surgeries, Avitus has received overwhelmingly positive feedback on the surgical experience and is leveraging its growing body of domain knowledge to solve other high-impact, unmet clinical needs.

Biorez is a medical device company developing regenerative implants for the orthopedic surgery market. Its lead product, the BioBrace, is an implant designed to improve outcomes for ACL reconstruction. BioBrace provides added strength to the surgical reconstruction, and acts as a scaffold for a patient’s cells to regenerate new tissue, improving the overall healing process. Over time, the BioBrace material is safely resorbed by the body, leaving new natural tissue and a healed ACL in its place. Biorez is planning a U.S. launch of BioBrace in 2020, and is developing a pipeline of devices for the sports medicine market.

Inbox Health is on a mission to make every patient payment experience convenient and clear, by changing how we engage, communicate, and transact with patients about how they are billed for their care. Its patient communication platform uses patient data to design billing processes that are specific to a patient’s situation and behavior patterns. Algorithms tailor the billing engagement for each practice and patient’s individual needs. Inbox Health powers intelligent communication between practices and patients using SMS, email, voice technology, and paper mail. Inbox Health focuses on the needs of third-party billing entities serving independent healthcare practices.

GlucoseZone is a patented and clinically-validated digital therapeutic for diabetes. Fitscript is pioneering the prescription of apps instead of drugs for the reduction, reversal and control of type 2 diabetes.

Diameter Health enables clinical insight through the normalization, cleansing, deduplication and enrichment of clinical data from across the care continuum. This creates a single, unified source of longitudinal structured patient information for improved care and actionable analytics. The Diameter Health platform empowers organizations that depend on multi-source data streams, such as health information exchanges (HIEs), accountable care organizations (ACOs), health systems and health plans, to realize greater value from their data.

P2 has brought simple, elegant green chemistry into the commercial mainstream. P2 uses patented oxidation technology to convert vegetable feedstocks into high-value specialty chemicals used in cosmetics, personal care, fragrance and other consumer markets. P2 recently started up its first commercial scale manufacturing plant in Connecticut. P2 has unlocked the vast potential of air-based oxidation using a unique process intensification approach that minimizes the environmental footprint, lowers cost and improves control. This enables simple vegetable feeds to be converted, at a very low cost, to high-performance renewable ingredients and intermediates used in consumer and industrial products.

Payveris’ uses the world’s best technology to deliver innovative, high-quality, and efficient digital payment and money movement solutions to financial institutions, their partners, and their customers. Its intelligent, cloud-based open-API MoveMoneySM platform empowers financial institutions to simplify, control, and extend their consumer and business digital payment, disbursement, and money movement capabilities—faster and more efficiently than anyone else in the industry. The Payveris team brings a wealth of experience from the payment, financial technology and banking industries to the mission of improving the overall digital payment and money movement experience for consumers, businesses, and financial institution employees.

P4 Technologies is the pioneer of cross-enterprise AI, which enables C-suite leaders to make better decisions and take faster actions. Using P4, leaders can manage across organizational silos based on a continuous stream of AI-generated recommendations that are fed back into existing systems. The P4 engine can be in place and generating business value within 90 days. P4 was created by the founders of Priceline. The company is based in Ridgefield, Connecticut.
TECH PANELS

9:10 AM | PANEL SESSION ONE

Digital Health Trends and Opportunities | Room: 2400

**Moderator**
Frank Milone (FML, LLP)

Patrice Wolfe (Caresource)

Tripp Peake (Long River Ventures)

Matt Storeygard (CT Innovations)

Lisa S. Stump (Yale New Haven Health)

John Rosano (Cigna)

10:10 AM | PANEL SESSION TWO

Artificial Intelligence: The Roles & Lifecycles of New Ventures | Room: 2400

**Moderator**
Chris McLeod (Elm Street Ventures)

Martin Wattenberg (Google Brain)

Rania Khalaf (IBM)

Devika Thapar (Wilbe Ventures)

Bhaskar Ghosh (8VC)

3:00 PM | PANEL SESSION THREE

Rise of the Family Office: Shaking up the Investment Landscape | Room: 2400

**Moderator**
James Gelfer (PitchBook Data, Inc.)

Eric S. Stein (ESS Capital Management, LP)

Brian Miller (North Sound Management)

Jay Newman (Ginzan Management Ltd)

Julia Paliare (RSL Investments)

*Download the eventdex app for detailed bio’s*
BIOTECH PANELS

9:10 AM | PANEL SESSION ONE

Breadth vs. Depth of Assets/Platform in Value Creation | Room: Zhang

Moderator
Kathryn Doyle
(Saul Ewing)

Geeta Vernuri
(Agent Capital)

Kuldeep Neote
(Eli Lilly and Company)

Stacey Seltzer
(Aisling Capital)

Adam Koppel
(Bain Capital)

Ben Dake
(RA Capital Management)

Stephen Knight
(F-Prime Capital)

10:10 AM | PANEL SESSION TWO

Business Development & Partnership Is there an Ideal Time? | Room: Zhang

Moderator
Dormer Stephen
(Shipman & Goodwin)

Sara Nayeem
(NEA)

Marian Nakada
(Johnson & Johnson Innovation)

Briggs Morrison
(MPM Capital)

Denis Patrick
(Pfizer Ventures)

Christine Brennan
(MRL Ventures Fund)

3:00 PM | PANEL SESSION THREE

Hot Areas for Investment and Why | Room: Zhang

Moderator
Farah Gerdes
(WSGR)

Jim Reddoch
(Royalty Pharma)

Alex Zisson
(HIG Biohealth Partners)

Peter Bak
(Back Bay Life Science Advisors)

Jason Hafler
(Sanofi Bioventures)

Claire Leurent
(Samsung Ventures)

Mike Dial
(Hatteras)

*Download the eventdex app for detailed bio’s
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Miranker</td>
<td>ADM Therapeutics: A platform for toxic rescue in oligomeropathies</td>
</tr>
<tr>
<td>Anna Pyle</td>
<td>Intronistat Therapeutics: Winning the Fight Against Fungal Pathogens</td>
</tr>
<tr>
<td>Ashok Chakraborty</td>
<td>Allexcel, Inc: Parkinson’s Disease (PD) Allogeneic Cell Replacement Therapeutic Approach with a Novel Neural Cell Line</td>
</tr>
<tr>
<td>Barbara Ehrlich</td>
<td>Center Pharm: NCS1 - A New Target for Wolfram Syndrome</td>
</tr>
<tr>
<td>Börk Balkan</td>
<td>NEVIVO: Connecticut’s Premier Vivarium Service Provider</td>
</tr>
<tr>
<td>Choukri Ben Mamoun</td>
<td>EliV5 Therapeutics: Breakthrough Therapy for Radical Cure of Fungal Infections</td>
</tr>
<tr>
<td>Christopher Bunick</td>
<td>First-in-class therapies targeting vimentin and keratin intermediate filaments</td>
</tr>
<tr>
<td>David Spiegel</td>
<td>Revel Pharmaceuticals: Identification of Glucosepane Cleaving Enzymes</td>
</tr>
<tr>
<td>Demitrios Braddock</td>
<td>Periozyme: Treating the Root Cause of Periodontal Disease through Cementum Regeneration</td>
</tr>
<tr>
<td>Donald M. Engelman</td>
<td>pHLP, Inc: Technology for Imaging and Targeted Therapy</td>
</tr>
<tr>
<td>Elsio A. Wunder</td>
<td>Nanoparticle delivery system as a multiplex protein vaccine strategy against leptospirosis</td>
</tr>
<tr>
<td>Eric Song</td>
<td>Immunaxis: Leveraging meningeal lymphatics to treat brain cancer</td>
</tr>
<tr>
<td>Jeffrey Bender</td>
<td>TargetSite Therapeutics: Harnessing the power of RNA-targeted oligonucleotide therapeutics</td>
</tr>
<tr>
<td>Jerome Schmitt</td>
<td>NanoEngineering Corp: Near Real-Time Viral Pathogen Recognition Technology</td>
</tr>
<tr>
<td>John Deacon</td>
<td>Cytosolix, Inc.: Improving small molecule therapy through targeted drug delivery to solid tumors</td>
</tr>
<tr>
<td>Jonathan Bogan</td>
<td>A novel enzymatic target for metabolic disease/obesity</td>
</tr>
<tr>
<td>Joseph Vinetz</td>
<td>LeptoX, Inc: Novel Immunochemistry Platform for Integrated Infectious Disease Diagnostics and Vaccine Development</td>
</tr>
<tr>
<td>Kumar Ashtekar/Mark Lemmon</td>
<td>First In line Inhibitor for FOP and DIPG</td>
</tr>
<tr>
<td>Lajos Pusztai</td>
<td>Novel antibody-drug conjugate to treat triple negative breast cancer and other cancer that express the target</td>
</tr>
<tr>
<td>Mark Fields</td>
<td>Development of Small Molecule Therapeutics for “Dry” Age-related Macular Degeneration (AMD)</td>
</tr>
<tr>
<td>Michael Van Zandt</td>
<td>New England Discovery Partners (NEDP): Making Molecules that Matter</td>
</tr>
<tr>
<td>Milica Vukmirovic</td>
<td>Vittix Therapeutics: Curing Idiopathic Pulmonary Fibrosis with Thyroid Hormone Mimetics</td>
</tr>
<tr>
<td>Nadia Ameen</td>
<td>Kinase inhibitors in treatment of Diarrheal Diseases</td>
</tr>
<tr>
<td>Natalie Ma/Farren Isaac</td>
<td>Pearl Bio: Transforming therapeutics and biomaterials development with synthetic biology</td>
</tr>
<tr>
<td>Neha Bhat</td>
<td>Hepatic Dyrk1b is an attractive target for the treatment of non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia</td>
</tr>
<tr>
<td>Paul Turner</td>
<td>Felix Biotechnology: Developing phages as evolution-proof therapies against drug-resistant bacteria</td>
</tr>
<tr>
<td>Richard Bucala</td>
<td>MIFCOR: MIF Therapy to prevent &amp; treat Chronic Obstructive Pulmonary Disease (COPD)</td>
</tr>
<tr>
<td>Sahar Esteghamat</td>
<td>Targeting the CELA2A as a Therapy for Atherosclerosis and Diabetes Type 2 and Metabolic Syndromes</td>
</tr>
<tr>
<td>Sean Bickerton/Philip Kong</td>
<td>Statera Therapeutics: Spatiotemporally Tuned Nanoparticles for unlocking the true potential of immunotherapy in autoimmune diseases</td>
</tr>
<tr>
<td>Shangqin Gao</td>
<td>Fast tracking cell fate transitions</td>
</tr>
<tr>
<td>Sidi Chen</td>
<td>EvolveImmune Therapeutics: Synergistic platforms for immunooncology and cell therapy</td>
</tr>
<tr>
<td>Smita Krishnaswamy</td>
<td>Machine Learning Accelerated Drug Discovery</td>
</tr>
<tr>
<td>Sorin Fedeleles</td>
<td>Asyst Therapeutics: A small molecule drug candidate targeting the Ire1α-XBP1 pathway for treatment of polycystic kidney disease</td>
</tr>
<tr>
<td>Timothy Siegert</td>
<td>Allyx Therapeutics: Advancing a unique disease modifying treatment for Alzheimer’s Disease</td>
</tr>
<tr>
<td>Ya Ha/Jonathan Ellman</td>
<td>Lkit Therapeutics: A Novel Strategy to Target p53 Mutation in Human Cancer</td>
</tr>
<tr>
<td>Yong Zhu</td>
<td>PiRNA-based Therapeutics: A novel platform for cancer treatment</td>
</tr>
</tbody>
</table>
**MEDTECH/TECH**

Albert Sinusas, MD  
**NuStent: Imageable Magnetic Biodegradable Intravascular Scaffold for Treatment of Atherosclerosis**

Alex Crich  
**Verivas Rapid Vein Harvester**

Amir Mor  
**ACIS: Automated cell injection systems**

Chi Liu  
**Artificial Intelligent Medical Imaging**

Elliott Brown  
**Pure Marrow: Revolutionizing Stem Cell Therapy**

Erik Gunther  
**PROTEOWISE: Unlocking the Protein World**

Hitten Zaveri  
**NeuroProbe: Reinventing Brain Care in the 21st Century**

Jan Schroers  
**SuperCool Metals: Transforming Metal Manufacturing**

Jerry Schmitt  
**NanoEngineering: Near Real-Time Viral Pathogen Recognition Technology**

Jessica Lewis  
**Expect With Me: Revolutionizing Prenatal Care by Reducing Costs and Improving Outcomes**

Jiheum Park  
**PAP-VR: Trans-catheter mitral valve repair system**

Jonathan Hochman  
**Universal Name System (UNS)**

Joran Booth  
**Omniskins: Turning Soft Objects into Robots**

Luiz Maracaja  
**VIDA MEDICAL DEVICES: Respiratory Apparatus for Lung Injury and Platform for Pulmonary Drug Delivery**

Marcus Alexander  
**GroupWise: Platform for network mapping and experiments**

Megan O'Connor  
**Nth Cycle: Redefining the Metal Supply Chain**

Mike Theran  
**CoRISMA: Next Generation Heart Assist Therapy**

Nicholas Chedid  
**Soli: A digital biomarker for mental health**

Peter Amos  
**Obsidian Advanced Manufacturing, LLC**

Sandra Saldana  
**ALVA Health: Wearable device for early stroke detection**

Sherry McKee  
**Lumme: Wearable Biosensors Promoting Behavior Change with Just-in-time Interventions**

Stuart Campbell/Stephanie Jacoby  
**PROPRIA: Engineered Human Heart Tissue**

Tarek Fahmy  
**INTEGRAID: Rethinking Adoptive Cell Therapy With Novel Bioprocessing Solutions**

Vivek Rajarathram  
**Hypnos Tech: Wearable EEG for fatigue management and error prevention**

Yusuf Ransome  
**DreamKit: A Web-Based Platform for Youth Experiencing Homelessness**

**CT INNOVATIONS**

<table>
<thead>
<tr>
<th>Logo</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="logo-abct.png" alt="ABCT" /></td>
<td><strong>ABCT</strong> Accelerator for Biosciences in Connecticut (ABCT)</td>
</tr>
<tr>
<td><img src="logo-affinimark.png" alt="Affinimark" /></td>
<td><strong>Affinimark</strong></td>
</tr>
<tr>
<td><img src="logo-convexity.png" alt="Convexity Scientific" /></td>
<td><strong>Convexity Scientific, LLCo</strong></td>
</tr>
<tr>
<td><img src="logo-enviro.png" alt="Enviro Power" /></td>
<td><strong>Enviro Power</strong></td>
</tr>
<tr>
<td><img src="logo-landsdowne.png" alt="Landsdowne Labs" /></td>
<td><strong>Landsdowne Labs</strong></td>
</tr>
<tr>
<td><img src="logo-biologics.png" alt="BiologicsMD" /></td>
<td><strong>Biologics MD</strong></td>
</tr>
<tr>
<td><img src="logo-phlatbed.png" alt="Phlatbed" /></td>
<td><strong>Phlatbed</strong></td>
</tr>
<tr>
<td><img src="logo-summit.png" alt="Summit Street Medical" /></td>
<td><strong>Summit Street Medical, LLC</strong></td>
</tr>
<tr>
<td><img src="logo-shoreline.png" alt="Shoreline Biome" /></td>
<td><strong>Shoreline</strong></td>
</tr>
<tr>
<td><img src="logo-krouzon.png" alt="Krouzon" /></td>
<td><strong>Krouzon</strong></td>
</tr>
</tbody>
</table>

*e-Poster list as of 4/29/19, for the most up-to-date list and map locations, download the Eventdex app.*
We see venture capital the way you see your business. Like no one else.
The Power of Collaboration.

“Innovation is the calling card of the future.”
- Anna Eshoo

Saul Ewing Arnstein & Lehr LLP is proud to support the Yale Innovation Summit and is delighted to continue to partner with Yale University to protect and commercialize its inventions.

Kathryn Doyle, Partner
Centre Square West
1500 Market Street, 38th Floor
Philadelphia, PA 19102
(215) 972-7734
We proudly support the 2019 Yale Innovation Summit and the ideas and investable innovations inspired by Yale Labs.

Contact: J. Dormer Stephen at (203) 836-2803 or dstephen@goodwin.com
Greenwich | Hartford | New Haven | New York | Stamford | Washington, DC
www.shipmangoodwin.com

Wiggin and Dana
proudly supports the
Yale Innovation Summit

For more information about the law firm of Wiggin and Dana, please contact
Evan Kipperman at ekipperman@wiggin.com or 203.363.7628 or
Paul Hughes at phughes@wiggin.com or 203.498.4321
Proud supporter of the 2019 Yale Innovation Summit

NEW HAVEN IS AMERICA’S
#1 relocation destination for millennials
#3 fastest growing city for venture capital investment
#4 densest concentration of federal R&D funding

ELM CITY
INNOVATION
COLLABORATIVE
Connected, Growing, Vibrant

Enabling the success of those with unique perspectives since 2002.
Klein Hersh is dedicated to delivering the top talent that propels science forward and helps life sciences and healthcare organizations prosper and grow.

220 Gibraltar Road, Suite 150
Horsham, PA 19044

+1 215.830.9211

www.kleinhersh.com

MERCK BUSINESS DEVELOPMENT & LICENSING

Merck is inventing because the world still needs cures for cancer, Alzheimer’s disease, HIV, and so many other causes of widespread suffering.

We believe that building strong partnerships is critical to solving these challenging diseases — to help people go on, unburdened, to experience, create and live their best lives.

Together we can invent for life.

Learn more at merck.com/licensing.
Proud to support the 2019 Yale Innovation Summit

Royalty Pharma

INNOVATION MATTERS

Wilson Sonsini Goodrich & Rosati

A unique perspective on a changing landscape

Faced with uncertain economic times and a volatile global marketplace, you need a law firm with the experience, skills, and resources to help you navigate shifting terrain. For more than 50 years, Wilson Sonsini Goodrich & Rosati has owed its success to being as innovative and cutting edge as the technology, life sciences, and growth enterprises that we represent. Let us show you why innovation matters in a law firm—and why you matter to us.

For more information, please visit wsgr.com
INVEST IN YOUR CLASSMATES.
WE DO.

We are a private venture capital fund exclusively for Yale alumni. Our fund invests in promising venture-backed companies founded or led by fellow alumni. If you are an accredited investor and looking for a smart, simple way to add VC to your portfolio, join us.

This year’s fund — Blue Ivy Ventures 4 — is opening soon.

Visit www.blueivyventures.com/alumni
Email invest@blueivyventures.com
Call 877-299-4538

The manager of Blue Ivy Ventures Fund 4 is Launch Angels Management Company, LLC, dba Alumni Ventures Group (AVG). AVG is a venture capital firm and is not affiliated with or endorsed by Yale University. For informational purposes only; offers of securities are made only pursuant to the fund’s offering documents, which describe the risks and other information that should be considered before investing.

Nurturing life science innovation through thoughtful strategy and transaction approaches

Proud to support the Yale Innovation Summit

www.bblsa.com | info@bblsa.com

Proud to support the Yale Innovation Summit

Yalies Investing In Yalies
WHAT IF THIS LITTLE GIRL COULD MEET THE PEOPLE WHO DEVELOPED THE DRUG FOR HER ULTRA-RARE DISEASE?

Watch Evie’s story at EvieCan.com

EMPOWERING DRUG DISCOVERY RESEARCH
Leading external innovation from target to IND and high-end CMC

AMAZING AMBITION

GOODWIN is proud to sponsor the 2019 YALE INNOVATION SUMMIT and congratulates entrepreneurial Yale faculty and students on their accomplishments and innovations.

www.goodwinlaw.com

Let Hamamatsu help you find the best solution for your application

Finding a solution with the ideal combination of sensitivity, speed, size, and cost can be a challenge with any application. So why not start your search with the company that practically has them all and the expertise to guide you to the right choice?

Learn more about detectors at www.hamamatsu.com
Toll-free: USA 1-800-524-0504

HAMAMATSU PHOTON IS OUR BUSINESS
PPG is a law firm specializing in biotechnology, pharmaceutical and chemical intellectual property law.

404.879.2150
pabstpatent.com

Yale New Haven Health is proud to support the 2019 Yale Innovation Summit.

Yale New Haven Health
Yale Office of Cooperative Research Team

The team at OCR is skilled at identifying technologies with market potential, navigating the patent process, connecting Yale researchers with academic and industry partners, building management teams and introducing startups to funding sources.

Managing Director
Jon Soderstrom

Business Development Professionals
John W. Puziss - Director of Business Development
David A. Lewin - Senior Associate Director of Business Development
Hong Peng - Associate Director of Business Development
Christopher Unsworth - Associate Director of Business Development
Lolahon Kadiri - Business Development Associate
Valarie Truax - Business Development Associate
Richard L. Anderson - Senior Business Development Associate

New Ventures & Blavatnik Fund for Innovation at Yale
Bill Wiesler - Director of New Ventures, Director of Blavatnik Fund
James G. Boyle - Executive Director, Faculty Entrepreneurship & Venture Development
Morag Grassie – Associate Director of Blavatnik Fund
Sorin Fedeles - Blavatnik Fellow
Caroline Rufo - Blavatnik Fellow
Timothy Siegert - Blavatnik Fellow
Milica Vukmirovic - Blavatnik Fellow

Entrepreneurs-in-Residence
Marc Appel
Konstantine Drakonakis
John Dexheimer
Brian Dixon
Colin Foster
Susan Froshauer
Gene Griffin

Brian Harvey
Jessica Hwang
Tom Jasinski
Kritstn King
Ron Lennox
Alexandra Mack
Bridget Martell

Tim Riley
Barry Schweitzer
Sapan Shah
Michael Singer
Julie Vance

Operations Team
Timothy Opstrup - Director of Finance & Administration
Kevin Mahoney - Assistant Business Manager
Diane K. Harmon - Director of Intellectual Property Administration
Natasha G. Samuels - Intellectual Property Manager
Tina Muzzy - Intellectual Property Compliance Associate
DawnMarie Portoff - Senior Licensing Compliance Professional
Connie Rowley - Financial Assistant
Olga Rivera - Operations Coordinator
Mercy A. Quaye - Marketing, Communications & Program Officer
Lesche Brunson - Administrative Assistant, Office of Cooperative Research
Lori Schrager - Administrative Assistant, Blavatnik & Faculty Entrepreneurship Program
Yale Office of Cooperative Research

Our Vision
Our vision is to make Yale the recognized leader in collaborating with investors and corporate partners in translating academic research into products that improve the health, welfare and prosperity of the global community.

Our Mission
OCR’s mission is to guide and support Yale researchers in the advancement of their innovations in furtherance of the University’s goal of fostering a culture of innovation, entrepreneurship and partnership across the Yale community, in order to:

• Enhance the research reputation of the university.
• Assist Yale in recruiting and retaining the best faculty, staff, and students.
• Catalyze local economic development through new venture startups.

OCR Central Campus
433 Temple Street
New Haven, CT 06511
203.436.8096
203.436.8086 (fax)
OCR@yale.edu

OCR Medical Campus
2 Church Street South
Suite 203
New Haven, CT 06519
203.785.6209
203.785.6165 (fax)
OCR@yale.edu

ocr.yale.edu
YALE INNOVATION SUMMIT
MAY 8, 2019

Download the eventdex app for full summit details.

YALEINNOVATIONSUMMIT.COM
#Summit19 #YaleInnovationSummit